SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Submission of Matters to a Vote of Security Holders

48

SIERRA ONCOLOGY, INC. (NASDAQ:SRRA) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07.

Submission of Matters to a Vote of Security
Holders.

On June13, 2017, Sierra Oncology, Inc. (the Company) held its
2017 Annual Meeting of Stockholders and the following proposals
were adopted:

1. Election of two Class II directors, Nicole Onetto and Daniel
Estes, each to serve a three-year term, which will expire at
the 2020 Annual Meeting of Stockholders and until such time
as their respective successors have been duly elected and
qualified or until such directors earlier resignation or
removal. The vote tally was as follows:

Nominees

Shares For

SharesWithheld

Broker Non-Votes

Nicole Onetto

27,077,529 1,133,359 10,665,206

Daniel Estes

27,688,459 522,429 10,665,206
2. Ratification of the appointment of Deloitte Touche LLP as the
Companys independent registered public accounting firm for
the fiscal year ending December31, 2017. The vote tally was
as follows:

Shares For

SharesAgainst

Shares Abstaining

Broker Non-Votes

38,333,028

494,541 48,525

The stockholders did not approve the stockholder proposal
requesting that the Companys Board of Directors take the
necessary steps under applicable state law to declassify the
Board of Directors so that all directors are elected annually.
The vote tally was as follows:

Shares For

SharesAgainst

Shares Abstaining

Broker Non-Votes

9,507,435

18,665,034 38,419 10,665,206

2


About SIERRA ONCOLOGY, INC. (NASDAQ:SRRA)

Sierra Oncology, Inc., formerly ProNAi Therapeutics, Inc., is a clinical-stage drug development company. The Company’s lead drug candidate, SRA737, is orally bioavailable small molecule inhibitor of Checkpoint kinase 1 (Chk1), a key cell cycle checkpoint and central regulator of the deoxyribonucleic acid (DNA) Damage Response (DDR) network. SRA737 is being investigated in approximately two Phase I clinical trials in patients with advanced cancer. Sierra Oncology is also advancing SRA141, an orally bioavailable small molecule inhibitor of the cell division cycle 7 kinase (Cdc7) kinase undergoing preclinical development. Sierra is building a range of pipeline of various oncology assets against targets at the edge of cancer biology. The Company’s SRA737 and SRA141 target the DDR network, a scientifically approach with far-reaching potential across oncology. SRA141 is an orally available small molecule inhibitor of Cdc7.

An ad to help with our costs